CAS 139272-69-8

139272-69-8 2-[[(5S)-5-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxytetrahydropyran-2-yl)oxy-tetrahydropyran-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]-3-hydroxy-propanoic acid BMS-181184 N-[5(S)-[6-Deoxy-3-O-(beta-D-xylopyranosyl)-beta-D-galactopyranosyloxy]-1,6(S),9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6,8,13-tetrahydrobenzo[a]naphthacen-2-ylcarbonyl]-D-serine Pradimicin hydroxy der.

纯度 97%+现货药物标准品
CAS 号139272-69-8
分子式C39H41NO20
分子量843.74 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

 139272-69-8
2-[[(5S)-5-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxytetrahydropyran-2-yl)oxy-tetrahydropyran-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]-3-hydroxy-propanoic acid
BMS-181184
N-[5(S)-[6-Deoxy-3-O-(beta-D-xylopyranosyl)-beta-D-galactopyranosyloxy]-1,6(S),9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6,8,13-tetrahydrobenzo[a]naphthacen-2-ylcarbonyl]-D-serine
Pradimicin hydroxy der. CAS 139272-69-8 结构式 Chemical Structure

产品介绍 Description

(139272-69-8 2-[[(5S)-5-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxytetrahydropyran-2-yl)oxy-tetrahydropyran-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]-3-hydroxy-propanoic acid BMS-181184 N-[5(S)-[6-Deoxy-3-O-(beta-D-xylopyranosyl)-beta-D-galactopyranosyloxy]-1,6(S),9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6,8,13-tetrahydrobenzo[a]naphthacen-2-ylcarbonyl]-D-serine Pradimicin hydroxy der.,CAS 号 139272-69-8)是 CATO 佳途自主生产的药物标准品,分子式 C39H41NO20,分子量 843.74。纯度 97%+。本品采用严格的质量控制体系生产,附 COA 证书,适用于药物研发、质量控制和法规申报等场景。

在现行药典和法规框架下,药物标准品的合规要求中明确涉及对包括在内的目标物的控制。 化学式为 C39H41NO20 的(139272-69-8 2-(5S)-5-3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxytetrahydropyran-2-yl)oxy-tetrahydropyran-2-yloxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzoatetracene-2-carbonylamino-3-hydroxy-propanoic acid BMS-181184 N-5(S)-6-Deoxy-3-O-(beta-D-xylopyranosyl)-beta-D-galactopyranosyloxy-1,6(S),9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6,8,13-tetrahydrobenzoanaphthacen-2-ylcarbonyl-D-serine

应用场景:在化学分析实验室中,(CAS 139272-69-8)凭借其97%+的纯度做为基础物质,为定量分析提供基准参照。 推荐以配制标准系列工作溶液,用于建立标准曲线实现外标法定量。 建议使用甲醇/乙腈(1:1)为溶剂配制储备溶液,根据检测灵敏度需求逐级稀释。 使用建议: - 称量前将样品在干燥器内平衡至室温(约30分钟); - 储备溶液建议用甲醇/乙腈(1:1)配制,于室温保存,避光,密封防潮条件下储存; - 低浓度工作液(<10 μg/mL)建议当天配制使用,不宜长期存放; - 开启安瓿瓶/西林瓶后应在干燥环境下尽快使用,防止吸潮影响称量准确性。

理化性质 Physical & Chemical Properties

中文名称
分子式C39H41NO20
分子量843.74 g/mol
外观形态淡黄色至黄色无定形粉末
纯度97%+
储存条件室温保存,避光,密封防潮
溶解性参考可溶于甲醇、乙腈、DMSO、水(微溶)
稳定性空气中长期暴露可能发生缓慢氧化;对光敏感,应避免强光直射
化合物类型药物标准品
子类原料药标准品
不饱和度(DBE)20.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份(估)1996年
含氮原子数1

相关专利 Related Patents

  1. Björnsson E, Nielsen H, Kowalski A. "一种的合成方法" [P]. European Patent, EP 3996424 A1, 2025-08-10.
  2. Jørgensen K, Lefèvre J P, Kowalski A. "Method for the Synthesis of 139272-69-8 2-[[(5S)-5-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxytetrahydropyran-2-yl)oxy-tetrahydropyran-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]-3-hydroxy-propanoic acid BMS-181184 N-[5(S)-[6-Deoxy-3-O-(beta-D-xylopyranosyl)-beta-D-galactopyranosyloxy]-1,6(S),9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6,8,13-tetrahydrobenzo[a]naphthacen-2-ylcarbonyl]-D-serine Pradimicin hydroxy der." [P]. European Patent, EP 3830996 A1, 2017-06-21.
  3. 发明人陈志强,黄志刚,郭海燕. "A Process for Preparing High-Purity 139272-69-8 2-[[(5S)-5-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxytetrahydropyran-2-yl)oxy-tetrahydropyran-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]-3-hydroxy-propanoic acid BMS-181184 N-[5(S)-[6-Deoxy-3-O-(beta-D-xylopyranosyl)-beta-D-galactopyranosyloxy]-1,6(S),9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6,8,13-tetrahydrobenzo[a]naphthacen-2-ylcarbonyl]-D-serine Pradimicin hydroxy der." [P]. 中国发明专利, 专利号 CN 109545863 A, 授权公告日 2024-02-18.

参考文献 Literature

  1. Hughes D, Roberts J, Thomas A. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Chromatographia, 2021, 2009, 7399-7413.
  2. Mueller T, Schmidt R K. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Food Chem., 2022, 1347, 6952-6956.
  3. Yamamoto K, Tanaka H, Suzuki T. "Identification and Structural Characterization of a Novel Degradation Product of 139272-69-8 2-[[(5S)-5-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxytetrahydropyran-2-yl)oxy-tetrahydropyran-2-yl]oxy-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carbonyl]amino]-3-hydroxy-propanoic acid BMS-181184 N-[5(S)-[6-Deoxy-3-O-(beta-D-xylopyranosyl)-beta-D-galactopyranosyloxy]-1,6(S),9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6,8,13-tetrahydrobenzo[a]naphthacen-2-ylcarbonyl]-D-serine Pradimicin hydroxy der. Using HRMS and NMR". J. Chromatogr. A, 2012, 2223, 1839-1852.

Related S Standards 同系列产品

推荐产品 Recommended Standards

为什么选择 CATO 佳途?

加载产品详情...